© 2020 MJH Life Sciences and OncLive. All rights reserved.
July 31, 2020
Ruth O’Regan, MD, discusses biomarkers of response to CDK4/6 inhibitors in breast cancer.
December 19, 2019
Ruth O’Regan, MD, discusses patient education as biosimilars are implemented into practice for breast cancer.
November 09, 2019
Ruth O’Regan, MD, discusses the prognostic value of pathologic complete response in HER2-positive breast cancer.
December 11, 2018
Ruth O’Regan, MD, division head, Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, discusses the role of chemotherapy as treatment continues to advance in breast cancer.